1. Chromosomes and Gene Expression
  2. Cancer Biology

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims  Is a corresponding author
  1. Constellation Pharmaceuticals, United States
  2. Genentech, United States
https://doi.org/10.7554/eLife.10483
Share this article
Cite this article
  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims
(2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
eLife 5:e10483.
https://doi.org/10.7554/eLife.10483
  2. Download BibTeX
  3. Download .RIS

Abstract

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple myeloma cell lines. Selective targeting of multiple myeloma cell lines through CBP/EP300 bromodomain inhibition is the result of direct transcriptional suppression of the lymphocyte-specific transcription factor IRF4, which is essential for the viability of myeloma cells, and the concomitant repression of the IRF4 target gene c-MYC. Ectopic expression of either IRF4 or MYC antagonizes the phenotypic and transcriptional effects of CBP/EP300 bromodomain inhibition, highlighting the IRF4/MYC axis as a key component of its mechanism of action. These findings suggest that CBP/EP300 bromodomain inhibition represents a viable therapeutic strategy for targeting multiple myeloma and other lymphoid malignancies dependent on the IRF4 network.

Article and author information

Author details

  1. Andrew R Conery

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Andrew R Conery, Employee of Constellation Pharmaceuticals.

  2. Richard C Centore

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Richard C Centore, Employee of Constellation Pharmaceuticals.

  3. Adrianne Neiss

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Adrianne Neiss, Employee of Constellation Pharmaceuticals.

  4. Patricia J Keller

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Patricia J Keller, Employee of Constellation Pharmaceuticals.

  5. Shivangi Joshi

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Shivangi Joshi, Employee of Constellation Pharmaceuticals.

  6. Kerry L Spillane

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Kerry L Spillane, Employee of Constellation Pharmaceuticals.

  7. Peter Sandy

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Peter Sandy, Employee of Constellation Pharmaceuticals.

  8. Charlie Hatton

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Charlie Hatton, Employee of Constellation Pharmaceuticals.

  9. Eneida Pardo

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Eneida Pardo, Employee of Constellation Pharmaceuticals.

  10. Laura Zawadzke

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Laura Zawadzke, Employee of Constellation Pharmaceuticals.

  11. Archana Bommi-Reddy

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Archana Bommi-Reddy, Employee of Constellation Pharmaceuticals.

  12. Karen E Gascoigne

    Genentech, South San Francisco, United States
    Competing interests
    Karen E Gascoigne, Employee of Genentech.

  13. Barbara M Bryant

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Barbara M Bryant, Employee of Constellation Pharmaceuticals.

  14. Jennifer A Mertz

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Jennifer A Mertz, Employee of Constellation Pharmaceuticals.

  15. Robert J Sims

    Constellation Pharmaceuticals, Cambridge, United States
    For correspondence
    robert.sims@constellationpharma.com
    Competing interests
    Robert J Sims, Employee of Constellation Pharmaceuticals.

Copyright

© 2016, Conery et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,108
    views
  • 1,296
    downloads
  • 95
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims
(2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
eLife 5:e10483.
https://doi.org/10.7554/eLife.10483

Share this article

https://doi.org/10.7554/eLife.10483

Categories and tags

Research organism

Further reading

    1. Chromosomes and Gene Expression

    Chromatin endogenous cleavage provides a global view of yeast RNA polymerase II transcription kinetics

    Jake VanBelzen, Bennet Sakelaris ... Jason H Brickner
    Research Article

    Chromatin immunoprecipitation (ChIP-seq) is the most common approach to observe global binding of proteins to DNA in vivo. The occupancy of transcription factors (TFs) from ChIP-seq agrees well with an alternative method, chromatin endogenous cleavage (ChEC-seq2). However, ChIP-seq and ChEC-seq2 reveal strikingly different patterns of enrichment of yeast RNA polymerase II (RNAPII). We hypothesized that this reflects distinct populations of RNAPII, some of which are captured by ChIP-seq and some of which are captured by ChEC-seq2. RNAPII association with enhancers and promoters - predicted from biochemical studies - is detected well by ChEC-seq2 but not by ChIP-seq. Enhancer/promoter-bound RNAPII correlates with transcription levels and matches predicted occupancy based on published rates of enhancer recruitment, preinitiation assembly, initiation, elongation, and termination. The occupancy from ChEC-seq2 allowed us to develop a stochastic model for global kinetics of RNAPII transcription which captured both the ChEC-seq2 data and changes upon chemical-genetic perturbations to transcription. Finally, RNAPII ChEC-seq2 and kinetic modeling suggests that a mutation in the Gcn4 transcription factor that blocks interaction with the NPC destabilizes promoter-associated RNAPII without altering its recruitment to the enhancer.

    1. Chromosomes and Gene Expression
    2. Microbiology and Infectious Disease

    Temporal transcriptional response of Candida glabrata during macrophage infection reveals a multifaceted transcriptional regulator CgXbp1 important for macrophage response and fluconazole resistance

    Maruti Nandan Rai, Qing Lan ... Koon Ho Wong
    Research Article Updated

    Candida glabrata can thrive inside macrophages and tolerate high levels of azole antifungals. These innate abilities render infections by this human pathogen a clinical challenge. How C. glabrata reacts inside macrophages and what is the molecular basis of its drug tolerance are not well understood. Here, we mapped genome-wide RNA polymerase II (RNAPII) occupancy in C. glabrata to delineate its transcriptional responses during macrophage infection in high temporal resolution. RNAPII profiles revealed dynamic C. glabrata responses to macrophages with genes of specialized pathways activated chronologically at different times of infection. We identified an uncharacterized transcription factor (CgXbp1) important for the chronological macrophage response, survival in macrophages, and virulence. Genome-wide mapping of CgXbp1 direct targets further revealed its multi-faceted functions, regulating not only virulence-related genes but also genes associated with drug resistance. Finally, we showed that CgXbp1 indeed also affects fluconazole resistance. Overall, this work presents a powerful approach for examining host-pathogen interaction and uncovers a novel transcription factor important for C. glabrata’s survival in macrophages and drug tolerance.